Introduction and Objective: To evaluate the impact of psychosocial factors, as assessed by the INSPIRE Questionnaire, and perceptions of technology efficacy (TES metrics) on glycemic outcomes and user acceptance of FCL systems in adults with type 1 diabetes.Methods: Data were analyzed from a cohort of 12 adults with T1D who participated in a 1-week at home study of FCL (NCT06041971). Key psychosocial variables, including INSPIRE baseline, TES Benefit, TES Burden, and TES efficacy, were assessed post FCL intervention and examined in relation to its glycemic outcomes, including Time<54, Time Below Range (TBR), Time in Range (TIR), Time Above Range (TAR), and Time>250 in FCL. Pearson correlations identified significant relationships, and insights were drawn regarding the influence of psychosocial factors and perceived efficacy on glycemic control and satisfaction with the FCL system.Results: Higher INSPIRE scores were significantly associated with lower perceived burden (r = -0.587, p < 0.01), better time-in-range (TIR; r = 0.575, p < 0.05) with reduced hypoglycemic exposure (r = -0.716, p < 0.01). TES Benefit strongly correlated with increased TIR (r = 0.805, p < 0.01) and lower hypoglycemic exposure (r = 0.707, p < 0.01), while higher TES Burden was linked to poorer TIR (r = -0.562, p < 0.05) and more hypoglycemic episodes (r = -0.716, p < 0.01). TES benefit strongly associates with overall system acceptance (r = 0.982, p < 0.01). TES efficacy did not correlate significantly with glycemic outcomes.Conclusion: Higher psychosocial engagement, as reflected by INSPIRE scores, and positive perceptions of system benefit are significantly associated with better glycemic outcomes and acceptance of FCL systems. These findings highlight the need for strategies that reduce burden and enhance benefit perception to optimize FCL system adoption, user satisfaction, and clinical outcomes.
A. Fernandes Moura B Batista: None. M. Moscoso-Vasquez: Other Relationship; Dexcom, Inc. Research Support; Tandem Diabetes Care, Inc, National Institute of Diabetes and Digestive and Kidney Diseases. S.A. Brown: Research Support; Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care, Inc, Tolerion, Roche Diabetes Care. Other Relationship; MannKind Corporation. M.D. DeBoer: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc, Medtronic. L. Gonder-Frederick: Other Relationship; HFS-Global LLC. M.D. Breton: Speaker’s Bureau; Sinocare Inc, Tandem Diabetes Care, Inc. Consultant; Roche Diabetes Care, Boydsense.
National Institutes of Health (NCT06041971)
Source link
Leave a Reply